ABT
The downgrade that wasn’t really a downgrade
Piper Sandler took a machete to Abbott Laboratories’ price target, lopping it down to $115 from $135. But before you panic, it kept the stock at Overweight, which is Wall Street for: “We still like the story, we just don’t love the price tag as much anymore.”
Why the haircut?
The catalyst was Abbott’s first-quarter results, where revenue came in lighter than expected on an organic growth basis. The big eyebrow-raiser was the medical device segment, especially the diabetes business, which looked more like a speed bump than a growth engine.
The market has noticed
Abbott’s not exactly hiding its bruises. The stock is down 23% year to date and is hanging out near its 52-week low of $93.92. That makes every target cut feel a little louder, because when a stock is already limping, the last thing it wants is a fresh round of analyst side-eye.
Big picture
This isn’t a thesis-breaking event, but it is another reminder that Abbott’s growth story needs a cleaner diabetes comeback and fewer “mixed” segment updates. If you own the stock, this is the part where you ask: is this just a patch of bad weather, or the start of a longer forecast?